Home/ Stocks/ ENLV

Enlivex Ltd. Ordinary Shares

ENLV XNAS

$1.10 +0.04 (+3.60%) ▲ 15-min delayed

Open

$1.09

High

$1.13

Low

$1.05

Volume

298.2K

Market Cap

$263.49M

About Enlivex Ltd. Ordinary Shares

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Employees: 36 Website →

Earnings & Analyst Ratings

Next Earnings: Mon, May 25, 2026

Calendar →

Related Market News

No specific coverage for ENLV yet. Check out our latest market news or earnings calendar.

Get ENLV Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Enlivex Ltd. Ordinary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.